Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
Neurology|May 6, 2018
Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRIKelly G Gwathmey, Reza Sadjadi, William B Horton, et al.
Annals of Neurology|March 13, 2008
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophyKathryn R Wagner, James L Fleckenstein, Anthony A Amato, et al.
Annals of the Rheumatic Diseases|February 21, 2023
Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositisIago Pinal-Fernandez, Angela Quintana, Jose Cesar Milisenda, et al.
Neurology|December 3, 2021
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG StudyRichard J Nowak, Christopher S Coffey, Jonathan M Goldstein, et al.
JAMA Neurology|February 18, 2020
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialJames F Howard, Richard J Nowak, Gil I Wolfe, et al.
BMJ Open|September 19, 2020
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North AmericaJoshua D Green, Richard J Barohn, Emanuela Bartoccion, et al.
Neurology|July 3, 2020
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B Aban, et al.
The Lancet. Neurology|January 30, 2019
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trialGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
The New England Journal of Medicine|August 11, 2016
Randomized Trial of Thymectomy in Myasthenia GravisGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
JAMA Neurology|March 24, 2020
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical TrialsMerit Cudkowicz, Marianne K Chase, Christopher S Coffey, et al.
Pageof 17